Physician profile
Elizabeth Shen
NPI 1396124889
$11,155.80
in general payments reported to CMS, 2019-2025
34 companies · $7,388 in 2025
The $7,388 reported for 2025 was more than what 92% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $145 · 2021: $224 · 2022: $1,161 · 2023: $679 · 2024: $1,101 · 2025: $7,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,375 · Food and Beverage: $2,417 · Travel and Lodging: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,375.00 |
| Food and Beverage | $2,416.52 |
| Travel and Lodging | $376.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,678.28 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $2,076.79 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $871.72 | 2022-2025 | Stellaris Elite, Envista Aspire Iol, Teneo |
| Alcon Vision LLC | $677.72 | 2019-2025 | Clareon |
| Johnson & Johnson Surgical Vision, INC. | $328.52 | 2022-2024 | Tecnis Simplicity, Tecnis Iol |
| Amgen INC. | $282.06 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $260.85 | 2022-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $219.75 | 2019-2022 | |
| Biotissue Holdings INC. | $214.75 | 2021-2025 | |
| Abbvie INC. | $177.37 | 2022-2025 | |
| Coopervision INC. | $143.40 | 2023-2025 | Misight Contact Lens |
| Immunogen, INC. | $136.14 | 2023 | Elahere |
| Sight Sciences, INC. | $125.53 | 2022 | |
| Apellis Pharmaceuticals, INC. | $120.79 | 2024 | Syfovre |
| Shire North American Group INC | $115.83 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nova Eye, INC. | $112.98 | 2024-2025 | |
| Oyster Point Pharma, INC. | $82.36 | 2022-2023 | Tyrvaya |
| Rxsight INC | $66.28 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Mallinckrodt Hospital Products INC. | $52.31 | 2021-2022 | |
| Carl Zeiss Meditec USA, INC. | $47.24 | 2023 | Artevo 800 |
| Dompe US, INC. | $43.34 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $40.41 | 2020-2021 | |
| Johnson & Johnson Vision Care, INC. | $35.95 | 2022 | |
| Glaukos Corporation | $31.30 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Tearlab Corp | $28.68 | 2021-2022 | |
| Optos, INC. | $27.76 | 2020 | |
| Allergan, INC. | $23.90 | 2022 | |
| Thea Pharma INC. | $23.47 | 2023 | |
| Eyevance Pharmaceuticals LLC | $19.78 | 2022 | |
| Kala Pharmaceuticals, INC. | $19.76 | 2020 | |
| Beaver-Visitec International, INC. | $19.26 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.17 | 2020 | |
| Harrow Eye, LLC | $17.62 | 2025 | |
| Horizon Therapeutics Plc | $14.73 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Shen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.